Patrick Hwu/X
Jan 20, 2025, 20:02
Patrick Hwu: Low Avidity T Cells Drive Cancer Control: A New Insight
Patrick Hwu, President and CEO at Moffitt Cancer Center, posted the following on LinkedIn:
“T cells recognize tumors through binding of their T-cell receptors (TCRs) to peptide antigens within MHC molecules.
What is the optimal strength of this receptor binding, known as ‘avidity,’ to mediate antitumor immunity?
In this work from the Srivastava Lab, low avidity T cells were found to drive cancer control, while high-affinity T cells were associated with T cell exhaustion.
This interesting (and unintuitive) insight may help guide future immunotherapy design.”
Low-avidity T cells drive endogenous tumor immunity in mice and humans
Authors: Summit Singhaviranon, Joseph P. Dempsey, Adam T. Hagymasi, Ion I. Mandoiu & Pramod K. Srivastava
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 20, 2025, 20:02
Jan 20, 2025, 19:50
Jan 20, 2025, 19:48
Jan 20, 2025, 19:46